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Identification and Characterization of
Butyrate-Producing Species in the Human Gut
Microbiome
Grace Maline

Abstract—Inflammatory Bowel Diseases (IBD) including ulcerative colitis, Crohn’s disease, and indeterminate colitis are
increasingly common conditions that places a high physical and
financial burden on individuals and global healthcare systems.
Though treatments exist for these conditions, their unpredictable
nature and causation make them difficult to manage consistently
across the variety of IBD patients. Additionally, many of these
treatments come with undesirable side effects or modes of
delivery. Therefore, we consider the use of Short Chain Fatty
Acids (SCFAs) such as butyrate, whose affects in the human gut
include decreased inflammation and decreased risk of colorectal
cancer. As butyrate is produced primarily by microbial species
within the human gut microbiome, this project’s aim was to
identify butyrate producing bacteria via metagenomic analysis
based on the presence of genes that are essential to pathways of
butyrate production. In total, 73 different potentially butyrateproducing species were identified and characterized. Species
identified include both gram-positive and gram-negative anaerobic bacteria belonging to the classes Clostridia, Fusobacteriia,
Negativicutes, Bacilli, and Bacteroidia. Of these, Clostridia was
the highest scoring class of bacteria.
Index Terms—IBD - Inflammatory Bowel Disease, SCFA Short Chain Fatty Acid

I. I NTRODUCTION

D

ISEASES involving inflammation of the digestive tract
are a highly prevalent and debilitating reality for many
individuals. Typically, these diseases are referred to as a collection of conditions known as Inflammatory Bowel Disease
(IBD). Conditions that fall under the umbrella term of IBD
include Crohn’s disease, ulcerative colitis, and indeterminate
colitis [1]. In 2017, around 6.8 million cases of IBD were
reported worldwide, which is almost twice the number of
cases reported just three decades prior [2]. As the prevalence
of this disease increases, so does its physical and financial
burden both on those who suffer from these conditions and
to global healthcare systems. Therefore, it is important that
special attention is paid to IBD to establish non-expensive and
effective treatments as well as preventative measures.
A. Motivation
IBD conditions are characterized by chronic, persistent
relapses of inflammation in the lower digestive tract [3]. They
are commonly associated with abdominal pain, rectal bleeding,
weight loss, and perianal disease. As a result, patients with
IBD report a large amount of discomfort and a substantial
reduction in quality of life [2]. Unfortunately, the causes of
IBD are often unknown and are overall poorly understand.

However, it is suspected that individuals contain genetic predispositions to immune triggers that result in the inflammatory
response [3]. It is often speculated that these triggers may
come in the form of environmental factors or as a result of the
interaction of host and microbial cells in the gut microbiome
[4].
Because of their high prevalence and mysterious origins,
much work in recent years has been dedicated to studying
these diseases, their causes, diagnosis, and treatments. It has
been found that induction of inflammation in the gut is often
related to two well-known pathways, namely the Nuclear
Factor-kappa B (NF-kB) pathway and the Mitogen-activated
protein kinase (MAPK) pathway [5]. Though targeting pathway intermediates such as TNF-alpha with anti-inflammatory
drugs and monoclonal antibodies can reduce gut inflammation,
drugs that are able to do so often come with significant
challenges [6]. Because they are non-specific to cell type, they
produce undesirable side effects. Additionally, administration
of the treatments may be invasive or uncomfortable [6].
Therefore, alternative prevention and treatments as they relate
to intervention in these pathways are actively sought and
studied.
Potential alternatives include Short Chain Fatty Acids
(SCFA), which have shown increasing popularity in recent
years. SCFAs such as butyrate, propionate, and acetate can
be shown to correlate with decreased gut inflammation and
decreased risk of colorectal cancer [7]. This is because SCFAs
are the preferred energy source for colonocytes [8]. Butyrate in
particular is a widely studied SCFA and accounts for about 70
percent of the energy supply for colonocytes, and inadequate
supplies of butyrate in the gut are closely tied to inflammation
and increased risk for cancer [7]. Butyrate acts by inhibition
of NF-kB related inflammatory pathways in epithelial cells as
well as by decreasing release of inflammatory cytokines [8].
Because of these anti-inflammatory effects, butyrate, among
other SCFAs can be utilized as dietary supplements for gut
health. However, there may be limitations to the effectiveness
and delivery of direct oral supplementation of butyrate. Orally
administrated butyrate products are often difficult to palate
due to intense odor and poor taste [9]. Especially for pediatric
patients, this can make it difficult or impossible to facilitate
regular daily doses [9]. Therefore, more work is needed to
investigate the potential for alternative methods of butyrate
delivery to cultivate its anti-inflammatory benefits.
Though less explored than direct oral supplementation and
prebiotic supplementation for existing flora, the possibility for
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a probiotic solution to this problem is very real. For this
to be cultivated, deeper exploration of the individual species
in the gut is needed both to identify the butyrate-producing
bacteria in the gut and to characterize them by their potential
to serve as probiotics [7]. Thus, this project will aim to make
steps toward that possibility by identifying and characterizing
microbial species in the human gut that could be butyrateproducers based on the presence of genes necessary for its
production.
B. Hypothesis
The objective of this project is to identify gut microbial
species that have butyrate production capabilities. Their ability
to produce butyrate will be based on the presence of pathway
genes within their genomes. The expected results will be a list
of human gut microbial species that possess such criteria.
In doing so, this project can provide a broad view for further
exploration of species that may be probiotic candidates. Future
in vitro and in vivo studies to further explore the resulting
microbial species could be established based on the findings
of this project. After identification, the resulting species will
be further evaluated by examining classes of bacteria by
phylogenetic analysis and ANOVA analysis.
It is currently speculated that butyrate-producing bacteria
are typically anaerobic, gram-positive firmicutes – mostly
belonging to clostridial clusters IV and XIVa [10]. It is
hypothesized that the results of these analyses will also fall
within these classes of bacteria.
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its final steps. These diverging branches are known as the
Butyrate Kinase pathway and the Butyryl-CoA:acetate CoA
transferase pathway [15]. Of these, the butyryl-CoA:acetate
CoA-transferase pathway is suspected to be more prevalent in
microbial species. Therefore, the butyryl-CoA:acetate CoAtransferase gene, encoding one of the pathway’s key enzymes,
has been shown to be one of importance in identifying
species that utilize this method of butyrate production [15].
Additionally, butyrate producing pathways with their essential
enzymes can also be observed in their overall context in KEGG
as a part of the Butanoate Metabolism pathway, (pathway id:
ko00650).

C. Background
Progress has already been made to begin identifying
butyrate-producing species. Early studies were limited to in
vitro observations of butyrate production and acetate utilization by species collected from fecal samples [11]. Enzymatic
assays and biochemical assays using primers and qPCR to
target important late pathway enzymes were popular methods
of studying butyrate production and identifying species [11],
[12]. However, these studies are limited by resources and
scope. These limitations can be supplemented by sequence
analysis and in silico approaches as proposed for this project.
An example of a successful in silico approach couples
qPCR enzyme analysis with metagenomic searches for the
the butyryl-CoA:acetate CoA-transferase gene sequence in a
handful of bacterial species suspected of butyrate production.
Both methods arrived at primarily the same conclusions and
same identified species, showing that both are adequate for
prediction of butyrate producing species [12], [13]. Therefore,
a widescale metagenomic analysis using pathway genes could
provide valuable insight into more microbes with these capabilities.
To identify bacteria capable of producing butyrate, it is
important to understand the pathways that bring about its
production. Butyrate is typically produced in a pathway that
branches from glucose fermentation during glycolysis [14].
Starting with acetyl-coA, a product of glucose fermentation,
there are two ways to obtain butyrate. These two pathways
shown in Figure 1 stem from a single pathway diverging at

Fig. 1. Butyrate Production Pathway Summary. This figure illustrates
the two common pathways of butyrate production in microbial gut species,
starting with acetyl-CoA. Each gray bubble represents a pathway enzyme,
and each white box represents a metabolite intermediate of the pathway.
The pathway diverges in the final steps into the Butyryl-CoA:acetate CoA
Transferase Pathway and the Butyrate Kinase Pathway.

II. M ATERIALS AND M ETHODS
The activities for this project can be broken down into
multiple steps for data collection, data generation, and
analysis. These activities and the flow of data associated
with them are summarized in Figure 2. All code for
these activities can be found in a public github repository
(https://github.com/gmaline/SeniorProject.git).
A. Data Sources
Sources of data for analysis will include whole genome
sequences of microbial species of the human gut microbiome that have been made publicly available by the
Human Microbiome Project (HMP) [16]. There are 457
microbial species from the gastrointestinal tract available
at https://www.hmpdacc.org/hmp/HMRGD/. Much work has
been put into sequencing and annotating genome data from
HMP since its development [17]. Therefore, the quality of the
reference genomes will be sufficient for this project.
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C. Collecting Pathway Enzyme Sequences

Fig. 2. Flow Diagram for Project Execution. This diagram illustrates step
by step the process for completing this project as broken into 6 main tasks: 2
rounds of Data Collection, Sequence Alignments, Scoring, ANOVA Analysis
and Phylogenetic Characterization.

In addition, sequences of the genes from the butyrate
production pathways will be pulled and investigated against
the genomes from HMP. The genes identified as important
in the butyryl-CoA:acetate CoA-transferase pathway and the
butyrate kinase pathway are summarized in Table 1.
Finally, for the phylogenetic analysis of the resulting
species, 16s rRNA sequences will be obtained from Silva
(https://www.arb-silva.de/). Silva is a high-quality ribosomal
RNA database supported by de.NBI [18].
B. Collecting Microbial Genomes
From the HMP1 data portal, the CDS of 457 different microbial species of the gastrointestinal tract were batch downloaded
in fasta format. To prep the sequences for further analysis,
some pre-processing was performed. Using the SeqIO python
library from Biopython, the fasta records in the larger CDS file
were read in [19]. Regular expression pattern searching with
the re python library allowed for the identification of species
name from the header of the fasta record. Using the species
name from the header, CDS sequences were separated into
individual fasta files for each species. This allowed for the easy
construction of blastdbs for each species for the subsequent
alignment analyses.

Additionally, the translated gene sequences of each enzyme
were obtained from NCBI and processed such that each protein
sequence was placed in its own fasta file with an identifiable
header for subsequent analyses. Protein sequence fasta headers
were as follows: thiolase, beta hydroxybutyryl-CoA dehydrogenase, crotonase, butyryl-CoA dehydrogenase, electron transfer flavoprotein alpha-subunit, electron transfer flavoprotein
beta-subunit, butyryl-COA-transferase, phoasephate butyryltransferase, butyrate kinase.

D. Sequence Alignments
For each of the species CDS fasta files, a temporary
nucleotide blastdb was built. Commands from the BLAST
Command Line Application from NCBI were run on command line from within a python script using the os python
library. For each species database built, a tblastn alignment
of each protein sequence was performed using the python
library NcbitblastnCommandline from Bio.Blast.Applications
[19]. The 4,000+ alignment results files were stored in their
own folder in an xml format.

Fig. 3. Pseudocode for Alignments. The pseudocode shown describes a
high level overview of how the sequence alignments were performed for the
purpose of this analysis.
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E. Scoring
To parse the xml results, the NCBIXML python library
was used from Bio.Blast [19]. Significant hits were stored as
csv output based on high scoring pairs with an e-value less
than .01. The results of parsing the xml files took note of
species, protein, percent identity, percent query coverage, and
the aligned query and subject sequences. After these results
were obtained, the resulting csv files were easily parsed and
scored such that only those species with one or more hits at
or above a 60 percent identity level were kept.
F. Phylogenetic and ANOVA Analyses
For comparison of the resulting potential butyrate-producing
species, 16s ribosomal RNA sequences were obtained from
Silva and compiled with identifiable headers [18]. A multiple
sequence alignment and newick tree format were obtained
from Clustal Omega [20]. The phylogenetic tree was visualized using Iroki, an automatic customization and visualization
of phylogenetic trees tool [21].
In addition to creating the phylogenetic tree, the resulting
scored species were labeled with taxon information. Breaking
them down into classes of bacteria an ANOVA analysis of the
scores was performed to look for differences in the strength
of the representation of butyrate producing species by class of
bacteria.
III. R ESULTS
At a 60 percent identity threshold, 73 species were found
to have at least one of the pathway enzymes in their genomes.
Though some species had partial hits for the butyrate kinase pathway, only the Butyryl-CoA:acetate CoA Transferase
pathway was represented in the results. Only 9 species had
all of the pathway enzymes present at the specified identity
threshold. However, many of the species that did not make the
cut do have some identity with the pathway enzymes below
and/or around the threshold. This is best seen by considering
Figures 4A-D in which the identities for each protein are
plotted with the threshold shown as a red horizontal line at
60 percent identity.

Fig. 4. Alignment Percent Identities. Results of Butyryl-CoA:acetate CoA
Transferase Pathway Protein Sequence Alignments against the 457 HMP
species. 73 total species were found to have at least 1 pathway protein present
at a 60 percent identity threshold. A summary of those hits are shown in AD. A: Species that contained all 7 pathway proteins at a 60 percent identity
threshold. B: Species that had 5-6 proteins at a 60 percent identity threshold.
C-D: Species that contained 1-4 proteins at a 60 percent identity threshold
broken into two parts for readability.

The scored results were categorized into three distinct categories, Definite Capability, Probable Capability, and Requires
Further Validation based on having scores of 7, 5-6, and 1-4
respectively. A breakdown of how many species fell into each
category is shown in Table 2.

Though it was hypothesized that the results would be
exclusively firmicutes, two other phyla of bacteria were also
found among the results of these analyses. These results are
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observed in Figure 5A. Firmicutes represented a majority of
the results (74 percent). However, 23 percent of the results
were Fusobacteria and 3 percent were Bacteroidota which
could lend itself to further evaluation of these phyla and their
metabolic activities. Similarly, it was suspected that the results
would consist of bacteria of the clostridial class exclusively.
The analysis results returned the representation of four additional classes of bacteria as summarized in Figure 5B. The
classes found include Clostridia, Fusobacteriia, Negativicutes,
Bacilli, and Bacteroidia.

Fig. 5. Breakdown of Phyla and Class from Potential Butyrate-Producing
Bacterial Results Three phyla and Five total classes were observed among
the results of the scored alignment analyses.

Using the scored data, an ANOVA analysis was performed
between the 5 classes of bacteria represented in Figure 5B.
Its purpose was to identify if there was a significant difference
in means among the scores for each class. The results of the
ANOVA analysis were significant at a 95 percent confidence
level with a p-vlaue of 0.0176. Thus, a Fischer’s LSD was
performed to identify the significant differences. As summarized in Figure 6 and Tables 3-4, the significant differences
indicate the Clostridia class is the highest scoring class among
Bacteroidia, Bacilli, and Fusobacteriia. Though it does appear
that this class is also higher scoring than Negativicutes, there
were not enough results in that class to confer statistical
significance.

Fig. 6. Statistical Distribution of Scores for 5 Classes of Potential
Butyrate-Producing Bacteria. Clostridia was among the highest scoring class
of bacteria.

Finally, a phylogenetic analysis of the resulting species
revealed the following phylogenetic tree (Figure 7). The tree
ultimately divides into two major groups: Group I and Group
II. Group I contains the Clostridia, Bacilli, Negativicutes,
and Bacteroidia, suggesting that these groups share more
similarities with the class of bacteria that were proposed in
this project’s original hypothesis. On the other hand, Group II
is composed entirely of the Fusobacteria class.
IV. D ISCUSSION
The results of this project found phyla and classes of
potential butyrate producing bacteria outside of those expected
from the literature. It was hypothesized that potential butyrate
producers are within the realm of the firmicutes phyla and
are majorly found in clostridial class clusters. However, the
results of these analyses indicated that Fusobacteria and Bacterioidota phyla as well as the classes Bacilli, Negativicutes,
Fusobacteriia, and Bacteroidia were also present.
Interestingly, though it was suspected that butyrate producing species include solely gram-positive anaerobes, the classes
identified in this analysis also indicate the help of anaerobic
gram-negative bacteria. Like Clostridium, the Bacillus class is
an anerobic gram-positive bacteria [22]. However, Negativicutes, Bacteroides, and Fusobaceteria are all negative straining
anaerobic bacteria [23], [24], [25]. Therefore, more exploration
is needed to better understand the type of bacteria with these
capabilities.
This project was limited due to the scope and time constraints of completion this Spring. Ways that this project could
have been improved with an extended timeline include the
inclusion of additional microbial genome datasets, such as the
integrated Human Microbiome Project (iHMP) or Culturalable
Reference Genome (CGR) for a wider breadth of species to
analyze [26], [27]. Additionally, the pathway proteins used
for the alignments could have provided a better standard for
comparison if a consensus sequence of multiple difference
versions of the pathway enzyme genes could have been used

SENIOR PROJECT IN BIOINFORMATICS, MAY 2021

6

This could provide guided directions for further analysis by
targeting only those species that have the properties to fare
well as a probiotic supplement. For instance, the class of
Bacteroidia would likely not be worth pursuing as a probiotic
as these types of bacteria are typically opportunistic pathogens
[24]. Their potential anti-inflammatory benefits would be
overshadowed by the risk of infection that they may pose if
they become unbalanced in the microbiome or if they invade
undesired tissues.
Some additional characteristics of a potential probiotic
could include ensuring the bacteria is capable of adhesion and
colonization in the colonic environment, having tolerance to
acid and bile salts, and maintaining stability and vitality in
the digestive tract [28]. If there are identifiable genes associated with these characteristics, preliminary analyses could be
performed in silico before testing in in vivo models.
V. C ONCLUSION
In conclusion, butyrate production via microbial species in
the human gut is a natural alternative to treating and preventing
inflammatory bowel disease, avoiding the various undesirable
side effects of current treatments. This project identified 73 potential butyrate producing species. Though the majority of the
high scoring results fell within the scope of the hypothesized
phyla and class of bacteria (firmicutes; clostridia), a handful
of others were identified that are phylogenetically related to
clostridia and might be worth further exploration. With further
analysis and validation, these bacteria could be candidates for
probiotic supplements for the treatment and prevention of IBD.
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Fig. 7. Phylogenetic Tree of Potential Butyrate-Producing Bacteria. The
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Group II contains the Fusobacteria class.
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